Loading…
← CockpitCompetitor Analysis › 300149.SZ ChemPartner PharmaTech Co., Ltd. Class AOpen in the cockpit ↗

ChemPartner PharmaTech Co., Ltd. Class A300149.SZCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services
Momentum neutral 44
Mkt cap
$582M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$30.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.8 pp
WACC 10.7%
Hurdle
+29 pp
Req g minus delivered
Close · CNYCN¥7.85
1D-2.9%
1W-10.0%
1M-4.0%
3M-30.8%
6M-16.8%
YTD-17.9%
1Y-30.0%
ATR %5.6%
52w lowhigh44.8% off high

What ChemPartner PharmaTech does

Employees: 1,771

ChemPartner PharmaTech at a glance

Size ChemPartner PharmaTech (300149.SZ) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $582M, the 3325th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.85 on 18 Nov 2026.

Performance Over six months the shares fell 16.8%, against -23.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 18.4% over the last twelve months (peer median +7.0%); the operating margin is 2.2% (peer median 6.3%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 4.0× (9th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.8 points below its cost of capital (10.7% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026300149.SZ 84Peer median 77
Six months, rebased to 100: ChemPartner PharmaTech against the median of its 20 peers (local-currency closes).

ChemPartner PharmaTech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.27BCN¥1.13BCN¥968MCN¥1.14BCN¥1.32B
Revenue growth—+17%-15%-14%—
Gross profitCN¥456MCN¥301MCN¥190MCN¥273MCN¥290M
EBITDAn/aCN¥170MCN¥77.8MCN¥125MCN¥149M
Net income-CN¥7.00MCN¥13.4M-CN¥226M-CN¥917MCN¥379M
Free cash flowCN¥84.3MCN¥128MCN¥98.6M-CN¥49.7M-CN¥73.4M
Capital expenditureCN¥87.2MCN¥62.5MCN¥69.2MCN¥201MCN¥336M
Total debtCN¥490MCN¥472MCN¥513MCN¥635MCN¥966M

Quarterly statements and history in the cockpit →

ChemPartner PharmaTech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%-10%0%603018IEG61462192301468POSTI22916030073013656027FM3009163001974071300215300355PAY3011726030603625300149.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. ChemPartner PharmaTech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%5×10×603018IEG61462192301468POSTI22916030073013656027FM300916300197300215300355PAY3011726030603625300149.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ChemPartner PharmaTech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%-25%0%25%50%603018IEG61462192POSTI22913013656027FM300197300215300355PAY301172603060300149.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ChemPartner PharmaTech is the large dot.

ChemPartner PharmaTech competitors and peer comparison

How ChemPartner PharmaTech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ChemPartner PharmaTech against its 20 peers (data as of 18 Nov 2026)
Measure300149.SZPeer medianRank in peer set
1-month return-4.0%-9.2%9th highest of 21
6-month return-16.8%-23.4%10th highest of 21
Distance from 52-week high-44.8%-37.4%9th lowest of 21
Revenue growth (TTM)+18.4%+7.0%5th highest of 21
Operating margin2.2%6.3%5th lowest of 21
EV / Sales3.1×4.0×9th cheapest of 21
Growth the price implies (Req g, 7 yrs)23.6%-2.4%4th most demanding of 16
Growth delivered (Del g)-5.2%+6.3%2nd lowest of 16
Hurdle (Req g minus delivered)+28.8 pp-3.9 pp3rd most demanding of 16
ROIC minus cost of capital-2.8 pp+0.4 pp8th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ChemPartner PharmaTech 300149.SZChina$582M-17%+18%2%3.1×23.6%-5.2%
China Design 603018.SSChina$582M-24%-8%7%0.8×-9.0%-5.1%
Italian Exhibition IEG.MIItaly$582M+33%+4%18%2.4×-2.4%+28.4%
Sporton International 6146.TWOTaiwan$580M-13%+8%30%3.4×-7.7%+5.0%
Medlive Technology 2192.HKHong Kong$579M-22%+6%29%2.1×-3.3%+23.8%
Pourin Special Welding Technology 301468.SZChina$577M-41%-4%5%6.5×n/an/a
Posti POSTI.HEFinland$575M+39%0%5%0.7×-4.1%-1.4%
LEPU ScienTech Medical Technology (Shanghai) 2291.HKHong Kong$574M+10%-4%42%5.3×-9.6%+28.0%
Danyang Syngen Intelligent Technology 603007.SSChina$591M-55%+298%-29%5.3×n/an/a
Matrix Design 301365.SZChina$593M-42%+9%4%3.9×26.1%+3.6%
Bengo4.com 6027.TJapan$571M+51%+22%14%5.0×14.6%+25.1%
Fiera Milano FM.MIItaly$593M-13%+46%22%1.6×-5.0%+38.8%
Shenzhen Longtech Smart Control 300916.SZChina$595M-25%-2%3%2.1×n/an/a
CECEP Techand Ecology and Environment 300197.SZChina$568M+11%+21%-271%13.9×29.1%-26.5%
Plus Alpha Consulting 4071.TJapan$598M-1%+13%39%4.1×n/an/a
Suzhou Electrical Apparatus Science Academy 300215.SZChina$566M-41%+8%9%5.9×6.9%-4.9%
M-Grass Ecology And Environment (Group) 300355.SZChina$565M-33%-23%-13%5.0×11.0%+0.5%
PayPoint PAY.LUnited Kingdom$564M+26%+8%21%1.2×-15.9%+21.4%
Sichuan Joyou Digital Technologies 301172.SZChina$563M-45%+18%4%6.0×57.6%+6.3%
China Testing & Certification International 603060.SSChina$563M-27%-6%4%2.4×11.3%+12.1%
Shanghai FourSemi Semiconductor 3625.HKHong Kong$562M-66%+3%-16%10.3×n/an/a

Questions

Which companies are ChemPartner PharmaTech's closest peers?
The cockpit's peer set: China Design (603018.SS), Italian Exhibition (IEG.MI), Sporton International (6146.TWO), Medlive Technology (2192.HK), Pourin Special Welding Technology (301468.SZ), Posti (POSTI.HE), LEPU ScienTech Medical Technology (Shanghai) (2291.HK), Danyang Syngen Intelligent Technology (603007.SS).
Is ChemPartner PharmaTech expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 4.0×, 9th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has ChemPartner PharmaTech stock performed?
Over six months to 18 Nov 2026 the shares returned -16.8% against -23.4% for the median peer; over one year -30.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.